{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:05:59Z","timestamp":1760148359067,"version":"build-2065373602"},"reference-count":23,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T00:00:00Z","timestamp":1728777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background: Glioblastoma is a challenge in neuro-oncology, with survival significantly influenced mainly by the extent of resection and molecular markers. Despite advancements, the prognosis for IDH-wildtype glioblastoma remains poor, particularly when surgical resection is not possible. However, some patients exhibit unexpectedly extended survival despite the extent of resection. This study aims to analyze the determinants that contribute to these atypical survival rates among glioblastoma patients who have had solely biopsy procedures. Methods: We conducted a retrospective analysis of patients diagnosed with IDH-wildtype glioblastomas at our institution from 2017 to 2021, who underwent biopsy only. This study focused on evaluating the impact of demographic characteristics, clinical features, molecular markers, and treatment modalities on survival outcomes (overall survival (OS) and progression-free survival (PFS)). Statistical analyses included survival analysis and logistic regression for evaluating associations between OS and pre-operative characteristics and post-operative treatments. Results: The cohort included 99 patients, with a median age at diagnosis of 65.5 years. Median OS and PFS were 6.0 and 3.6 months, respectively. The multivariate analysis revealed that higher Karnofsky Performance Status (KPS) scores before biopsy, no contrast uptake on imaging, and any adjuvant therapy, particularly the use of bevacizumab, were independently associated to increased OS (HR = 0.97, p = 0.009. HR = 0.7, p = 0.015; HR = 0.27, p = 0.002, respectively). Out of 99 patients, 77.8% survived past the 3-month threshold, with 87.0% of this receiving adjuvant treatment. Only 8% of patients survived past 24 months, and in this group of patients, MGMT methylation was observed in just 25% of cases. Kaplan\u2013Meier analysis indicated a better prognosis with any type of adjuvant therapy across all patients, particularly so in those with KPS \u2265 70. Age did not significantly affect survival outcomes (OR = 1.00, p = 0.835). Conclusion: Our findings reveal that any adjuvant treatment (whether chemotherapy and radiotherapy combined, chemotherapy alone, or bevacizumab), no contrast uptake on imaging, and higher pre-operative KPS are key determinants of survival in IDH-wildtype glioblastoma and should therefore be considered when deciding whether to perform a biopsy.<\/jats:p>","DOI":"10.3390\/biomedicines12102327","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T05:47:58Z","timestamp":1728884878000},"page":"2327","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Survival Determinants in Glioblastoma: An Insight into Biopsy-Only Patient Outcomes"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9817-3900","authenticated-orcid":false,"given":"Jo\u00e3o Meira","family":"Gon\u00e7alves","sequence":"first","affiliation":[{"name":"Neurosurgery Department, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Oporto, Portugal"},{"name":"Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4584-1228","authenticated-orcid":false,"given":"Francisca","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Neurology Department, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Oporto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3972-7544","authenticated-orcid":false,"given":"Bruno","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Neurosurgery Department, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Oporto, Portugal"},{"name":"Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"given":"Patr\u00edcia","family":"Pol\u00f3nia","sequence":"additional","affiliation":[{"name":"Neurosurgery Department, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Oporto, Portugal"},{"name":"Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0888-3325","authenticated-orcid":false,"given":"Paulo","family":"Linhares","sequence":"additional","affiliation":[{"name":"Neurosurgery Department, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Oporto, Portugal"},{"name":"Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"\u015aledzi\u0144ska, P., Bebyn, M.G., Furtak, J., Kowalewski, J., and Lewandowska, M.A. (2021). Prognostic and Predictive Biomarkers in Gliomas. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910373"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network, Brat, D.J., Verhaak, R.G., Aldape, K.D., Yung, W.K., Salama, S.R., Cooper, L.A., Rheinbay, E., Miller, C.R., and Vitucci, M. (2015). Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N. Engl. J. Med., 372, 2481\u20132498.","DOI":"10.1056\/NEJMoa1402121"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11060-020-03606-5","article-title":"Cytoreductive surgery in the management of newly diagnosed glioblastoma in adults: A systematic review and evidence-based clinical practice guideline update","volume":"150","author":"Domino","year":"2020","journal-title":"J. Neuro-Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1227\/01.neu.0000317304.31579.17","article-title":"Extent of resection and survival in glioblastoma multiforme: Identification of and adjustment for bias","volume":"62","author":"Stummer","year":"2008","journal-title":"Neurosurgery"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/nop\/npaa037","article-title":"Neuro-Oncology Practice Clinical Debate: Early treatment or observation for patients with newly diagnosed oligodendroglioma and small-volume residual disease","volume":"8","author":"Fogh","year":"2020","journal-title":"Neuro-Oncol. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e762","DOI":"10.1016\/j.wneu.2018.08.163","article-title":"Biopsy Versus Subtotal Versus Gross Total Resection in Patients with Low-Grade Glioma: A Systematic Review and Meta-Analysis","volume":"120","author":"Yang","year":"2018","journal-title":"World Neurosurg."},{"key":"ref_9","first-page":"1","article-title":"Comparing Glioblastoma Surgery Decisions Between Teams Using Brain Maps of Tumor Locations, Biopsies, and Resections","volume":"3","author":"Robe","year":"2019","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_10","first-page":"227","article-title":"Long-term survival of glioblastoma: A systematic analysis of literature about a case","volume":"33","year":"2022","journal-title":"Neurocirugia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"112913","DOI":"10.1016\/j.ejca.2023.05.002","article-title":"Long-term survival with IDH wildtype glioblastoma: First results from the ETERNITY Brain Tumor Funders\u2019 Collaborative Consortium (EORTC 1419)","volume":"189","author":"Hertler","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1158\/1078-0432.CCR-13-0017","article-title":"Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations","volume":"19","author":"Hartmann","year":"2013","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/neuonc\/noac193","article-title":"Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group","volume":"25","author":"Karschnia","year":"2022","journal-title":"Neuro-Oncology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/neuonc\/nos089","article-title":"miR-181d: A predictive glioblastoma biomarker that downregulates MGMT expression","volume":"14","author":"Zhang","year":"2012","journal-title":"Neuro Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Brown, N.F., Ottaviani, D., Tazare, J., Gregson, J., Kitchen, N., Brandner, S., Fersht, N., and Mulholland, P. (2022). Survival Outcomes and Prognostic Factors in Glioblastoma. Cancers, 14.","DOI":"10.3390\/cancers14133161"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jocn.2018.05.002","article-title":"Ten-year survival in glioblastoma. A systematic review","volume":"54","author":"Tykocki","year":"2018","journal-title":"J. Clin. Neurosci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1002\/cncr.30063","article-title":"Concurrent chemoradiotherapy versus radiotherapy alone for \u201cbiopsy-only\u201d glioblastoma multiforme","volume":"122","author":"Kole","year":"2016","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"ii4","DOI":"10.1093\/noajnl\/vdac091","article-title":"The future of brain tumor liquid biopsies in the clinic","volume":"4","author":"Brennan","year":"2022","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/nop\/npv007","article-title":"Early cognitive function tests predict early progression in glioblastoma","volume":"2","author":"Lee","year":"2015","journal-title":"Neuro-Oncol. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/neuonc\/nou349","article-title":"Biopsy versus partial versus gross total resection in older patients with high-grade glioma: A systematic review and meta-analysis","volume":"17","author":"Almenawer","year":"2015","journal-title":"Neuro-Oncology"},{"key":"ref_21","first-page":"476","article-title":"Managing Glioblastoma in the Elderly Patient: New Opportunities","volume":"31","author":"Snyder","year":"2017","journal-title":"Oncology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/neuonc\/nox133","article-title":"Glioblastoma in elderly patients: Solid conclusions built on shifting sand?","volume":"20","author":"Wick","year":"2018","journal-title":"Neuro-Oncology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.4103\/0028-3886.333476","article-title":"Health-related Quality of Life Assessment in Patients with Malignant Gliomas","volume":"69","author":"Taskiran","year":"2021","journal-title":"Neurol. India"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/12\/10\/2327\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:12:40Z","timestamp":1760112760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/12\/10\/2327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,13]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["biomedicines12102327"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines12102327","relation":{},"ISSN":["2227-9059"],"issn-type":[{"type":"electronic","value":"2227-9059"}],"subject":[],"published":{"date-parts":[[2024,10,13]]}}}